Adam's Biotech Scorecard Adam Feuerstein STAT Plus: An under-the-radar biotech finds FDA more receptive to an alternative to Covid vaccines
Adam's Take Adam Feuerstein STAT Plus: Soleno Therapeutics responds to short seller’s Prader-Willi drug safety claims
Adam's Take Adam Feuerstein STAT Plus: FDA ‘uncertainty’ forces Krystal Biotech to shutter cancer drug trial
Adam's Biotech Scorecard Adam Feuerstein STAT Plus: Are we sure Vinay Prasad’s ouster is positive for biotech?
Adam's Take Adam Feuerstein STAT Plus: The year is half over. Here’s where the biotech industry stands
Adam's Take Adam Feuerstein STAT Plus: Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout
Adam's Take Adam Feuerstein STAT Plus: What’s next for Sarepta Therapeutics with gene therapy under fire?
Adam's Take Adam Feuerstein STAT Plus: MoonLake Immunotherapeutics is for sale? This sounds like a cry for help
Adam's Take Adam Feuerstein STAT Plus: What to know about Summit Therapeutics’ looming clinical trial readout
Adam's Take Adam Feuerstein STAT Plus: Vinay Prasad is outraged, and now at the FDA. How will biotech deal?
Adam's Take Adam Feuerstein STAT Plus: The trade war hits pause, but the biotech doom loop carries on
Adam's Take Adam Feuerstein STAT Plus: Burst PIPEs? So-so returns for biotech’s once-buzzy financing vehicle
Adam's Take Adam Feuerstein STAT Plus: Sutro Bio joins biotech’s zombie army. When will this insanity end?
Adam's Biotech Scorecard Adam Feuerstein STAT Plus: Thoughts, takes, and burning biotech questions as the beginning of the end of the year approaches
